NASDAQ$PAYS

Paysign Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Paysign's financial performance was impacted by stimulus check distributions and unemployment subsidies, but the company added three new plasma centers and signed agreements with four new entrants in the plasma collection space.

Paysign reported financial results for the first quarter of 2021, which were negatively impacted by stimulus measures. However, the company is optimistic about a rebound as vaccinations increase and restrictions lift. Paysign added three new plasma centers during the quarter and expects to add a total of 60 new plasma centers this year. The company anticipates revenue to reach between $29.0 million and $32.0 million for the full year 2021.

  • First quarter results were impacted by stimulus check distributions and unemployment subsidies.
  • Three new plasma centers were added during the quarter.
  • Agreements signed with four new entrants in the plasma collection space.
  • Expects to exit 2021 with at least 400 plasma centers.

Headline financials

Total Revenue

$6.28M

Previous: $10.6M-40.6%
EPS (adj)

-$0.03

Previous: $0.05-160.0%
Avg. Revenue/Plasma Ctr

$5.26K

No prior period
Capital Expenditures

-$125K

Previous: -$954K+86.9%
Free Cash Flow

-$1.75M

Previous: $587K-397.8%
Net Income

-$1.62M

Previous: $1.54M-205.4%
Operating Income

-$1.63M

Previous: $1.39M-217.1%
Gross Profit

$2.83M

Previous: $5.72M-50.5%
Cash & Equivalents

$65.3M

Previous: $54.8M+19.1%
Total Assets

$77.7M

Previous: $63.9M+21.6%
Stock-Based Comp

$636K

Previous: $724K-12.1%

Revenue & EPS history

Paysign · Revenue · Quarterly

$6.28M

Q1 2021-40.6%vs Q1 2020
Beat estimate in 5 of 13 quarters(38%)
ActualEstimate

Forward guidance

For the full year 2021, Paysign expects total revenue to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%, and adjusted EBITDA to be in the range of $0.35 million to $1.90 million. Gross profit margins are expected to be approximately 45.0%, or an increase of 640 basis points over 2020. Operating expenses are expected to increase modestly to $18.0 million to $18.5 million, or 2.0% to 4.9%.

Tailwinds

  • Total revenue expected to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%.
  • Adjusted EBITDA expected to be in the range of $0.35 million to $1.90 million.
  • Gross profit margins are expected to be approximately 45.0%, an increase of 640 basis points over 2020.
  • Plasma revenue could reach $27.5 million for the full year 2021.
  • Plasma revenue increase by an additional $10.0 million in 2022.

Headwinds

  • First quarter continued to be impacted by COVID-19 and government stimulus measures.
  • Second-quarter results are expected to be only slightly better than the first-quarter results.
  • Recovery in the business is dependent on unemployment subsidies ending in early September.
  • Operating expenses are expected to increase modestly to $18.0 million to $18.5 million, or 2.0% to 4.9%.
  • Uncertainty remains around the extent and timing of the potential future spread or mitigation of COVID-19.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+16.3%

Avg return

Earnings day

+5.5%

Avg return

5 days after

+9.6%

Avg return

30 days after

43%

26 / 60 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-12.6%-12.0%
Q4 2025+37.3%+52.8%+65.0%
Q3 2025+0.2%-8.8%+0.4%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro